PAM
IOVA icon

Premier Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Premier Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,760
Closed -$748K – 181
2021
Q2 		$748K Buy
+28,760
New +$748K 0.11% 115
2021
Q1 		– Sell
-6,951
Closed -$323K – 196
2020
Q4 		$323K Sell
6,951
-12,870
-65% -$511K 0.07% 132
2020
Q3 		$652K Buy
19,821
+12,081
+156% +$370K 0.17% 74
2020
Q2 		$212K Sell
7,740
-3,545
-31% -$117K 0.07% 117
2020
Q1 		$338K Buy
+11,285
New +$299K 0.14% 79

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Premier Asset Management's IOVA Position: Q3 2021 in Review

Premier Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 28,760 shares — an estimated $748K sold.

Premier Asset Management first reported a position in IOVA in Q1 2020 and held it in 5 quarters. The position peaked at $748K in Q2 2021. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Premier Asset Management reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Premier Asset Management sold 28,760 Iovance Biotherapeutics shares in Q3 2021, an estimated $748K.
  • Premier Asset Management first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 5 quarters.
  • Premier Asset Management's Iovance Biotherapeutics position peaked at $748K in Q2 2021.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Premier Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.